Teva Pharmaceutical Industries EBITDA 2010-2024 | TEVA

Teva Pharmaceutical Industries EBITDA for the quarter ending December 31, 2024 was $0.238B, a 76.69% decline year-over-year.

  • Teva Pharmaceutical Industries 2024 EBITDA was 0.756B, a 52.33% decline from 2023.
  • Teva Pharmaceutical Industries 2023 EBITDA was 1.586B, a 278.4% decline from 2022.
  • Teva Pharmaceutical Industries 2022 EBITDA was -0.889B, a 129.2% decline from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Teva Pharmaceutical Industries EBITDA 2010-2024 | TEVA

  • Teva Pharmaceutical Industries 2024 EBITDA was 0.756B, a 52.33% decline from 2023.
  • Teva Pharmaceutical Industries 2023 EBITDA was 1.586B, a 278.4% decline from 2022.
  • Teva Pharmaceutical Industries 2022 EBITDA was -0.889B, a 129.2% decline from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Dr Reddy's Laboratories (RDY)$11.2B
BridgeBio Pharma (BBIO)$6.9B
Bausch Health Cos (BHC)$2.4B
Supernus Pharmaceuticals (SUPN)$1.9B
Amphastar Pharmaceuticals (AMPH)$1.5B
Personalis (PSNL)$412M
Taysha Gene Therapies (TSHA)$336M
Assembly Biosciences (ASMB)$81M
Sol-Gel Technologies (SLGL)$16M
Evoke Pharma (EVOK)$8M
Teligent (TLGT)$0M